Patent ID: 9017944
Filing Date: 2015-04-28
Classification: A61P,C12Q

Abstract:
1. A method for providing a prognosis of breast cancer in a human subject having an estrogen receptor-positive and node-negative breast cancer following therapeutic treatment targeting the endocrine pathway, comprising: obtaining from the subject a biological sample comprising breast cancer cell genomic DNA to be analyzed for methylation state; contacting the genomic DNA in the sample with at least one agent for distinguishing between methylated and non-methylated CpG dinucleotide sequences; determining the CpG methylation state of at least one target CpG dinucleotide sequence within a region between positions 1859 and 2144 of SEQ ID NO: 23; and providing the prognosis of breast cancer based on the methylation state, wherein hypomethylation as compared to a control sample is indicative of a high probability of at least one of: a relapse-free survival, a disease-free survival, a slower progression of metastases, or a response of metastases to treatment with tamoxifen and hypermethylation as compared to a control sample is indicative of a low probability of at least one of: relapse-free survival, disease-free survival, slower progression of metastases, or response of metastases to treatment with tamoxifen, thereby providing the prognosis of breast cancer in a human subject having an estrogen receptor-positive and node-negative breast cancer following therapeutic treatment targeting the endocrine pathway, wherein the therapeutic treatment targeting the endocrine pathway is selected from the group consisting of administration of estrogen receptor modulators, estrogen receptor down-regulators, aromatase inhibitors, ovarian ablation, LHRH analogs and centrally acting drugs influencing estrogen production.